Small interfering RNAs (siRNAs) are valuable reagents for efficient gene silencing in a sequence‑specific manner via the RNA interference (RNAi) pathway. The current synthetic siRNA structure consists of symmetrical duplexes of 19‑21 base pairs (bp) with 2 nucleotide (nt) 3' overhangs. In this study, we report that an asymmetric siRNA (asiRNA) consisting of 17 bp duplex region (17 bp asiRNA) exhibited potent activity in inhibiting bcl-2 gene expression and cancer cell proliferation in vitro. Importantly, this asiRNA structure significantly reduced off‑target silencing by the sense strand. To improve the stability of the 17 bp asiRNA, we synthesized a series of chemically modified 17 bp asiRNAs. Further experiments showed that in comparison with the 17 bp asiRNA, the 17 bp asiRNA‑M2, one of the modified 17 bp asiRNAs, exhibited a comparable gene silencing activity and an improved stability in vitro. Furthermore, the 17 bp asiRNA‑M2 with a proteolipid micelle delivery system can effectively suppress the growth of H22 and BGC 803 tumors in vivo. These results suggest that the chemically modified asiRNAs may have potential as an effective therapeutic approach for cancer gene therapy in the future.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3892/ijo.2012.1691 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Design, Screening and Development of Asymmetric siRNAs Targeting the Oncogene in Triple-Negative Breast Cancer.
Biomol Ther (Seoul)
January 2025
Research Institute of Pharmaceutical Science, Department of Pharmacy, Seoul National University, College of Pharmacy, Seoul 08826, Republic of Korea.
Triple-negative breast cancer (TNBC) is a subtype of breast cancer that lacks hormone receptor and Her2 (ERBB2) expression, leaving chemotherapy as the only treatment option. The urgent need for targeted therapy for TNBC patients has led to the investigation of small interfering RNAs (siRNAs), which can target genes in a sequence-specific manner, unlike other drugs. However, the clinical translation of siRNAs has been hindered by the lack of an effective delivery system, except in the case of liver diseases.
View Article and Find Full Text PDFEfficacy of Asymmetric siRNA Targeting Androgen Receptors for the Treatment of Androgenetic Alopecia.
Mol Pharm
January 2023
Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea.
Article Synopsis
- This study investigates the use of a specialized small interfering RNA, called cp-asiAR, designed to target and silence the androgen receptor, which is linked to hair loss in androgenetic alopecia (AGA).
- In mouse models of AGA induced by dihydrotestosterone (DHT), the injection of cp-asiAR led to reduced levels of the androgen receptor and promoted hair growth, suggesting its effectiveness in treating this condition.
- The treatment was also found to downregulate harmful signaling pathways associated with hair loss without causing significant toxicity, highlighting its potential as a new therapeutic option for AGA.
Asymmetric siRNA targeting the bcl‑2 gene inhibits the proliferation of cancer cells in vitro and in vivo.
Int J Oncol
January 2013
Department of Biological Science and Technology, Nanjing University, Nanjing, People's Republic of China.
Small interfering RNAs (siRNAs) are valuable reagents for efficient gene silencing in a sequence‑specific manner via the RNA interference (RNAi) pathway. The current synthetic siRNA structure consists of symmetrical duplexes of 19‑21 base pairs (bp) with 2 nucleotide (nt) 3' overhangs. In this study, we report that an asymmetric siRNA (asiRNA) consisting of 17 bp duplex region (17 bp asiRNA) exhibited potent activity in inhibiting bcl-2 gene expression and cancer cell proliferation in vitro.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!